Evrard D, Hourseau M, Couvelard A, Paradis V, Gauthier H, Raymond E, Halimi C, Barry B, Faivre S
Department of Otorhinolaryngology, Bichat Hospital, Paris, France.
Pathology Department, Bichat Hospital, Paris 7 University, Paris, France.
Oncoimmunology. 2020 Nov 19;9(1):1844403. doi: 10.1080/2162402X.2020.1844403.
In head and neck squamous cell carcinoma (HNSCC), data from studies using checkpoint-inhibiting antibodies that target programmed death 1 (PD-1) or its ligand the programmed death ligand 1 (PD-L1) demonstrated outstanding clinical activity. Translational investigations also suggested some correlations between therapeutic response and PD-L1 expression in tumor tissue. We comprehensively summarize results that have evaluated PD-L1 expression in HNSCC. We discuss flaws and strength of current PD-1/PD-L1 detection, quantification methods and the evaluation of PD-L1 as a prognostic and theragnostic biomarker. Understanding tumor microenvironment may help understanding resistance to checkpoint inhibitors, designing clinical trials that can exploit drug combinations.
在头颈部鳞状细胞癌（HNSCC）中，使用靶向程序性死亡1（PD-1）或其配体程序性死亡配体1（PD-L1）的检查点抑制抗体的研究数据显示出卓越的临床活性。转化研究也提示了肿瘤组织中治疗反应与PD-L1表达之间的一些相关性。我们全面总结了评估HNSCC中PD-L1表达的结果。我们讨论了当前PD-1/PD-L1检测、定量方法以及将PD-L1作为预后和治疗生物标志物评估的缺陷与优势。了解肿瘤微环境可能有助于理解对检查点抑制剂的耐药性，设计能够利用药物联合的临床试验。
